EMA Approval: Lenacapavir (Sunlenca), a First-In-Class HIV Capsid Inhibitor

In August 2022, the European Medicines Agency granted Marketing Authorization to lenacapavir (Sunlenca), the first-in-class bi-annually dosed HIV capsid inhibitor indicated for multidrug-resistant HIV-1 infection.

This Premium deep dive into Sunlenca includes:

  • the industry context
  • the clinical data
  • the target rationale
  • the mechanism of action
  • and the drug’s origins.
lenacapavir (Sunlenca), HIV capsid inhibitor, Twice yearly injection after a 2-week oral loading, For adults with multidrug-resistant HIV-1 infection, Gilead Sciences
Lenacapavir (Sunlenca), chemical structure

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more:

Join the Drug Hunter mailing list

to get free content and resources weekly. Trusted by > 5,500 drug hunters worldwide. Unsubscribe anytime.


Join Subscribers from